library.onepin.app/mk-677 Peptide Education Library
Education only, not medical advice 21+ Every dose is an example to finalize with a licensed provider

OnePin Peptide Library · Growth Hormone

Growth Hormone Peptide Not FDA-approved · investigational

MK-677

Ibutamoren · MK677 · Nutrobal

MK-677 (ibutamoren mesylate) is a non-peptide, orally active growth hormone secretagogue that mimics the action of ghrelin by binding to the growth hormone secretagogue receptor (GHS-R1a). Unlike growth hormone releasing peptides (GHRPs), MK-677 is not a peptide and has excellent oral bioavailability. It stimulates the pituitary gland to release growth hormone (GH) in a pulsatile, physiological pattern, and significantly increases circulating levels of both GH and IGF-1 without suppressing the hypothalamic-pituitary axis.,MK-677 was developed by Merck and investigated in multiple Phase II clinical trials for growth hormone deficiency, muscle wasting, osteoporosis, and age-related frailty. These trials demonstrated consistent and sustained increases in GH and IGF-1 levels (IGF-1 increases of 40-60% above baseline) that persisted with chronic daily dosing for up to 2 years. However, Merck discontinued clinical development and MK-677 was never submitted for FDA approval. It remains an investigational compound.,A critical consideration with MK-677 is its effect on insulin sensitivity and blood glucose. As a ghrelin mimetic, it increases appetite (which is a desired effect for some, but problematic for others) and can worsen insulin resistance, raise fasting glucose, and increase HbA1c. This metabolic trade-off was a significant factor in Merck's decision not to pursue approval and is an important consideration for long-term use. MK-677 also increases cortisol and prolactin in some individuals, though usually within normal ranges.

Quick Start
Route
Oral
Start low
10-25mg
Frequency
daily, preferably before bed
Timing
Can be taken fasted or with food. Taking before bed may maximize sleep-related GH pulse amplification.

Oral: Bedtime dosing preferred (GH pulse during sleep, reduces daytime hunger). Take with or without food. Continuous or 5-on-2-off.

Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.

Tiered Protocols · lowest first
Quick Start
Conservative start
10-25mg · Oral · daily, preferably before bed
Lowest starting point. Hold about a week to assess tolerance before stepping up.
10-25mg
daily, preferably before bed
Standard
Standard Oral
12.5-25 mg · Oral · Daily
human clinical trial · Nass et al. 2008 (Ann Intern Med)
12.5-25 mg
Daily
Intermediate
Higher Dose
25 mg · Oral · Daily
anecdotal · community
25 mg
Daily
Reconstitution CalculatorU-100
050100u
Draw to
units
01

How it works

Binds to the ghrelin/growth hormone secretagogue receptor (GHS-R1a) in the hypothalamus and pituitary, mimicking endogenous ghrelin. This stimulates growth hormone-releasing hormone (GHRH) neurons and directly activates pituitary somatotrophs, producing pulsatile GH release that mirrors the natural secretory pattern.,Amplifies GH pulse amplitude without altering pulse frequency, preserving the physiological GH secretion pattern. Also reduces somatostatin (GH-inhibiting hormone) tone, further facilitating GH release. The result is sustained elevation of both GH and IGF-1 levels without the tachyphylaxis seen with continuous GH administration.,As a ghrelin mimetic, MK-677 activates hypothalamic appetite centers (NPY/AgRP neurons), increasing hunger and food intake. It also modulates glucose metabolism through GHS-R1a-mediated effects on pancreatic islets and hepatic glucose output, which can worsen insulin sensitivity.

Binds to the ghrelin/growth hormone secretagogue receptor (GHS-R1a) in the hypothalamus and pituitary, mimicking endogenous ghrelin. This stimulates growth hormone-releasing hormone (GHRH) neurons and directly activates pituitary somatotrophs, producing pulsatile GH release that mirrors the natural secretory pattern.,Amplifies GH pulse amplitude without altering pulse frequency, preserving the physiological GH secretion pattern. Also reduces somatostatin (GH-inhibiting hormone) tone, further facilitating GH release. The result is sustained elevation of both GH and IGF-1 levels without the tachyphylaxis seen with continuous GH administration.,As a ghrelin mimetic, MK-677 activates hypothalamic appetite centers (NPY/AgRP neurons), increasing hunger and food intake. It also modulates glucose metabolism through GHS-R1a-mediated effects on pancreatic islets and hepatic glucose output, which can worsen insulin sensitivity.

02

What to expect

Early
Days 1–7

Days 1-7: Increased appetite and improved sleep quality are the first noticeable effects. Mild water retention begins. GH/IGF-1 elevation starts within 2-3 days.

03

Evidence

HumanPresent
AnimalPresent
In-vitroPresent
2008Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial · Nass R et al, Annals of Internal Medicine ↗peer reviewed
1998MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism · Murphy MG et al, Journal of Clinical Endocrinology and Metabolism ↗peer reviewed
1999Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults · Murphy MG et al, Journal of Bone and Mineral Research ↗peer reviewed
1996Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects · Chapman IM et al, Journal of Clinical Endocrinology and Metabolism ↗peer reviewed
04

Interactions & stacking

What's safe to combine, and what belongs in a separate pin.

Safe & synergistic

Testosterone CypionateOften used together in hormone optimization protocols without pharmacological conflict
BPC-157Different mechanisms - GH elevation and tissue repair can be combined safely
EpithalonTelomerase activation and GH elevation address different longevity pathways
PregnenoloneHormone precursor support and GH elevation are independent pathways

Keep separate

SemaglutideMK-677 increases appetite and worsens insulin resistance, directly opposing GLP-1 agonist metabolic benefits
TirzepatideMK-677 appetite stimulation and glucose elevation counteract GIP/GLP-1 agonist effects
SurvodutideMK-677 worsens insulin resistance and increases appetite, opposing GLP-1/glucagon agonist goals
RetatrutideMK-677 appetite stimulation and metabolic effects conflict with triple incretin agonist therapy
05

Pharmacokinetics

Illustrative plasma concentration · 24 h
Half-life
~4-6 hours (effective duration ~24 hours due to sustained IGF-1 elevation)
Peak · Tmax
~1-2 hours oral
Elimination
~20-30 hours (parent compound). IGF-1 elevation persists ~24 hours.
Activity
24 hours (GH pulsatility and IGF-1 elevation sustained with daily dosing)

Storage. Store at room temperature in a cool, dry place. Protect from moisture and light. Oral compound - no reconstitution needed.

06

Regulatory status

Investigational compound - never FDA-approved. Clinical development discontinued by Merck. Not a dietary supplement. Listed as a prohibited substance by WADA. Classified as a research chemical.

Put it to work

Calculate, log & track

Open MK-677 straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.

Open MK-677 in the app →

Go deeper

The guide & community

The complete MK-677 walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.

Join the community ↗
Open in app Community